{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:49:00Z","timestamp":1791845340883,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013207","name":"Reckitt Benckiser Pharmaceuticals","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100013207","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013207","name":"Reckitt Benckiser Pharmaceuticals","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100013207","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013207","name":"Reckitt Benckiser Pharmaceuticals","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100013207","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013207","name":"Reckitt Benckiser Pharmaceuticals","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100013207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ibuprofen is one of the most commonly used analgesic and antipyretic drugs in children. However, its potential causal role in childhood asthma pathogenesis remains uncertain. In this systematic review, we assessed the association between ibuprofen administration in children and the risk of developing or exacerbating asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched MEDLINE, Embase, Cochrane Library, CINAHL, Web of Science, and Scopus from inception to May 2022, with no language limits; searched relevant reviews; and performed citation searching. We included studies of any design that were primary empirical peer-reviewed publications, where ibuprofen use in children 0\u201318 years was reported. Screening was performed in duplicate by blinded review. In total, 24 studies met our criteria. Data were extracted according to PRISMA guidelines, and the risk of bias was assessed using RoB2 and NOS tools. Quantitative data were pooled using fixed effect models, and qualitative data were pooled using narrative synthesis. Primary outcomes were asthma or asthma-like symptoms. The results were grouped according to population (general, asthmatic, and ibuprofen-hypersensitive), comparator type (active and non-active) and follow-up duration (short- and long-term).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Comparing ibuprofen with active comparators, there was no evidence of a higher risk associated with ibuprofen over both the short and long term in either the general or asthmatic population. Comparing ibuprofen use with no active alternative over a short-term follow-up, ibuprofen may provide protection against asthma-like symptoms in the general population when used to ease symptoms of fever or bronchiolitis. In contrast, it may cause asthma exacerbation for those with pre-existing asthma. However, in both populations, there were no clear long-term follow-up effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ibuprofen use in children had no elevated risk relative to active comparators. However, use in children with asthma may lead to asthma exacerbation. The results are driven by a very small number of influential studies, and research in several key clinical contexts is limited to single studies. Both clinical trials and observational studies are needed to understand the potential role of ibuprofen in childhood asthma pathogenesis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-024-03179-3","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T10:03:09Z","timestamp":1724666589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The association between ibuprofen administration in children and the risk of developing or exacerbating asthma: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Luke","family":"Baxter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M.","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aomesh","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeccah","family":"Slater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olutoba","family":"Sanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nutan","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"key":"3179_CR1","unstructured":"WHO. Asthma [Internet]. 2023 [cited 2023 Apr 4]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/asthma"},{"key":"3179_CR2","doi-asserted-by":"crossref","unstructured":"Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. European Respiratory Journal [Internet]. 2022 Jan 1 [cited 2022 Apr 27];59(1). https:\/\/erj.ersjournals.com\/content\/59\/1\/2102730","DOI":"10.1183\/13993003.02730-2021"},{"issue":"10100","key":"3179_CR3","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"Vos","year":"2017","unstructured":"Vos T, Murray CJL, GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the global burden of Disease Study 2016. Lancet. 2017;390(10100):1211\u201359.","journal-title":"Lancet"},{"issue":"9998","key":"3179_CR4","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(15)00156-7","volume":"386","author":"R Beasley","year":"2015","unstructured":"Beasley R, Semprini A, Mitchell EA. Risk factors for asthma: is prevention possible? Lancet. 2015;386(9998):1075\u201385.","journal-title":"Lancet"},{"issue":"3","key":"3179_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2165\/00148581-200709030-00008","volume":"9","author":"K Schr\u00f6r","year":"2007","unstructured":"Schr\u00f6r K. Aspirin and Reye syndrome: a review of the evidence. Paediatr Drugs. 2007;9(3):195\u2013204.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"3179_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0091-6749(99)70106-5","volume":"104","author":"A Szczeklik","year":"1999","unstructured":"Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol. 1999;104(1):5\u201313.","journal-title":"J Allergy Clin Immunol"},{"key":"3179_CR7","unstructured":"NHS. nhs.uk. 2020 [cited 2023 Apr 4]. Medicines for babies and children. https:\/\/www.nhs.uk\/conditions\/baby\/health\/medicines-for-babies-and-children\/"},{"key":"3179_CR8","unstructured":"NHS. nhs.uk. 2022 [cited 2023 Apr 4]. Who can and cannot take ibuprofen for children. https:\/\/www.nhs.uk\/medicines\/ibuprofen-for-children\/who-can-and-cannot-take-ibuprofen-for-children\/"},{"key":"3179_CR9","unstructured":"NHS. nhs.uk. 2022 [cited 2023 Apr 4]. Who can and cannot take paracetamol for children. https:\/\/www.nhs.uk\/medicines\/paracetamol-for-children\/who-can-and-cannot-take-paracetamol-for-children\/"},{"issue":"12","key":"3179_CR10","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1016\/j.clinthera.2007.12.021","volume":"29","author":"D Kanabar","year":"2007","unstructured":"Kanabar D, Dale S, Rawat M. A review of ibuprofen and acetaminophen use in febrile children and the occurrence of asthma-related symptoms. Clin Ther. 2007;29(12):2716\u201323.","journal-title":"Clin Ther"},{"issue":"1","key":"3179_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10787-016-0302-3","volume":"25","author":"DJ Kanabar","year":"2017","unstructured":"Kanabar DJ. A clinical and safety review of Paracetamol and Ibuprofen in children. Inflammopharmacology. 2017;25(1):1\u20139.","journal-title":"Inflammopharmacology"},{"issue":"5","key":"3179_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2165\/00148581-200406050-00001","volume":"6","author":"RE Kauffman","year":"2004","unstructured":"Kauffman RE, Lieh-Lai M. Ibuprofen and increased morbidity in children with asthma: fact or fiction? Paediatr Drugs. 2004;6(5):267\u201372.","journal-title":"Paediatr Drugs"},{"issue":"3","key":"3179_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1345\/aph.1M332","volume":"44","author":"CA Pierce","year":"2010","unstructured":"Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother. 2010;44(3):489\u2013506.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"3179_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12890-020-1102-5","volume":"20","author":"M Sherbash","year":"2020","unstructured":"Sherbash M, Furuya-Kanamori L, Nader JD, Thalib L. Risk of wheezing and asthma exacerbation in children treated with Paracetamol versus Ibuprofen: a systematic review and meta-analysis of randomised controlled trials. BMC Pulm Med. 2020;20(1):72.","journal-title":"BMC Pulm Med"},{"key":"3179_CR15","doi-asserted-by":"crossref","unstructured":"Southey ER, Soares-Weiser K, Kleijnen J. Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever. Current medical research and opinion [Internet]. 2009 Sep [cited 2022 May 19];25(9). https:\/\/pubmed.ncbi.nlm.nih.gov\/19606950\/","DOI":"10.1185\/03007990903116255"},{"issue":"10","key":"3179_CR16","doi-asserted-by":"publisher","first-page":"e2022398","DOI":"10.1001\/jamanetworkopen.2020.22398","volume":"3","author":"E Tan","year":"2020","unstructured":"Tan E, Braithwaite I, McKinlay CJD, Dalziel SR. Comparison of Acetaminophen (paracetamol) with Ibuprofen for Treatment of Fever or Pain in children younger than 2 years: a systematic review and Meta-analysis. JAMA Netw Open. 2020;3(10):e2022398.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"3179_CR17","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1183\/09031936.93.03050588","volume":"3","author":"A Szczeklik","year":"1990","unstructured":"Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J. 1990;3(5):588\u201393.","journal-title":"Eur Respir J"},{"issue":"8","key":"3179_CR18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s13312-015-0698-7","volume":"52","author":"YM Su","year":"2015","unstructured":"Su YM, Huang CS, Wan KS. Short-term ibuprofen treatment and pulmonary function in children with asthma. Indian Pediatr. 2015;52(8):691\u20133.","journal-title":"Indian Pediatr"},{"issue":"1","key":"3179_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Reviews. 2015;4(1):1.","journal-title":"Syst Reviews"},{"key":"3179_CR20","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","volume":"349","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.","journal-title":"BMJ"},{"key":"3179_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 Guideline Statement. J Clin Epidemiol. 2016;75:40\u20136.","journal-title":"J Clin Epidemiol"},{"key":"3179_CR22","doi-asserted-by":"crossref","unstructured":"McGowan J, Sampson M, Salzwedel DM, Cogo E, Lefebvre C, PRESS Peer Review of Electronic Search Strategies. : 2015 Guideline Explanation and Elaboration (PRESS E&E). CADTH Methods and Guidelines [Internet]. 2016 [cited 2022 Mar 3]; https:\/\/www.cadth.ca\/press-peer-review-electronic-search-strategies-2015-guideline-explanation-and-elaboration","DOI":"10.1016\/j.jclinepi.2016.01.021"},{"key":"3179_CR23","unstructured":"Haddaway NR, Grainger MJ, Gray CT. citationchaser: An R package and Shiny app for forward and backward citations chasing in academic searching [Internet]. Zenodo; 2021 [cited 2023 Jan 17]. https:\/\/zenodo.org\/record\/4543513"},{"key":"3179_CR24","unstructured":"Thomas J, Graziosi S, Brunton J, Ghouze Z, O\u2019Driscoll P, Bond M et al. EPPI-Reviewer: advanced software for systematic reviews, maps and evidence synthesis [Internet]. EPPI-Centre, UCL Social Research Institute, University College London; 2022. http:\/\/eppi.ioe.ac.uk\/cms\/Default.aspx?tabid=2914"},{"key":"3179_CR25","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"3179_CR26","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M et al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. 2008 [cited 2022 May 23]. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"issue":"4","key":"3179_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153\u201360.","journal-title":"Evid Based Ment Health"},{"issue":"5","key":"3179_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","volume":"27","author":"S Yusuf","year":"1985","unstructured":"Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27(5):335\u201371.","journal-title":"Prog Cardiovasc Dis"},{"issue":"6","key":"3179_CR29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/BF03256907","volume":"30","author":"H Kokki","year":"2010","unstructured":"Kokki H, Kokki M. Ketoprofen versus Paracetamol (acetaminophen) or ibuprofen in the management of fever: results of two randomized, double-blind, double-dummy, parallel-group, repeated-dose, multicentre, phase III studies in children. Clin Drug Investig. 2010;30(6):375\u201386.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"3179_CR30","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1542\/peds.104.4.e39","volume":"104","author":"SM Lesko","year":"1999","unstructured":"Lesko SM, Mitchell AA. The safety of acetaminophen and ibuprofen among children younger than two years old. Pediatrics. 1999;104(4):e39.","journal-title":"Pediatrics"},{"issue":"12","key":"3179_CR31","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/jama.1995.03520360043037","volume":"273","author":"SM Lesko","year":"1995","unstructured":"Lesko SM, Mitchell AA. An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. JAMA. 1995;273(12):929\u201333.","journal-title":"JAMA"},{"issue":"5","key":"3179_CR32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40272-017-0237-1","volume":"19","author":"S Luo","year":"2017","unstructured":"Luo S, Ran M, Luo Q, Shu M, Guo Q, Zhu Y, et al. Alternating Acetaminophen and Ibuprofen versus monotherapies in improvements of distress and reducing refractory fever in Febrile children: a Randomized Controlled Trial. Paediatr Drugs. 2017;19(5):479\u201386.","journal-title":"Paediatr Drugs"},{"issue":"3","key":"3179_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/1060028016678006","volume":"51","author":"I Matok","year":"2017","unstructured":"Matok I, Elizur A, Perlman A, Ganor S, Levine H, Kozer E. Association of Acetaminophen and Ibuprofen Use with Wheezing in Children with Acute Febrile illness. Ann Pharmacother. 2017;51(3):239\u201344.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"3179_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1136\/adc.74.2.164","volume":"74","author":"J McIntyre","year":"1996","unstructured":"McIntyre J, Hull D. Comparing efficacy and tolerability of Ibuprofen and Paracetamol in fever. Arch Dis Child. 1996;74(2):164\u20137.","journal-title":"Arch Dis Child"},{"issue":"2","key":"3179_CR35","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jaci.2014.07.065","volume":"135","author":"JE Sordillo","year":"2015","unstructured":"Sordillo JE, Scirica CV, Rifas-Shiman SL, Gillman MW, Bunyavanich S, Camargo CA, et al. Prenatal and infant exposure to acetaminophen and ibuprofen and the risk for wheeze and asthma in children. J Allergy Clin Immunol. 2015;135(2):441\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"3179_CR36","doi-asserted-by":"publisher","first-page":"e0203770","DOI":"10.1371\/journal.pone.0203770","volume":"13","author":"P Walsh","year":"2018","unstructured":"Walsh P, Rothenberg SJ. Wheezing after the use of acetaminophen and or ibuprofen for first episode of bronchiolitis or respiratory tract infection. PLoS ONE. 2018;13(9):e0203770.","journal-title":"PLoS ONE"},{"issue":"6","key":"3179_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/000992280104000602","volume":"40","author":"A Wong","year":"2001","unstructured":"Wong A, Sibbald A, Ferrero F, Plager M, Santolaya ME, Escobar AM, et al. Antipyretic effects of dipyrone versus ibuprofen versus acetaminophen in children: results of a multinational, randomized, modified double-blind study. Clin Pediatr (Phila). 2001;40(6):313\u201324.","journal-title":"Clin Pediatr (Phila)"},{"key":"3179_CR38","doi-asserted-by":"publisher","first-page":"e6760","DOI":"10.7717\/peerj.6760","volume":"7","author":"LS Fu","year":"2019","unstructured":"Fu LS, Lin CC, Wei CY, Lin CH, Huang YC. Risk of acute exacerbation between acetaminophen and ibuprofen in children with asthma. PeerJ. 2019;7:e6760.","journal-title":"PeerJ"},{"issue":"2","key":"3179_CR39","doi-asserted-by":"publisher","first-page":"E20","DOI":"10.1542\/peds.109.2.e20","volume":"109","author":"SM Lesko","year":"2002","unstructured":"Lesko SM, Louik C, Vezina RM, Mitchell AA. Asthma morbidity after the short-term use of ibuprofen in children. Pediatrics. 2002;109(2):E20.","journal-title":"Pediatrics"},{"issue":"41","key":"3179_CR40","doi-asserted-by":"publisher","first-page":"e5109","DOI":"10.1097\/MD.0000000000005109","volume":"95","author":"PC Lo","year":"2016","unstructured":"Lo PC, Tsai YT, Lin SK, Lai JN. Risk of asthma exacerbation associated with nonsteroidal anti-inflammatory drugs in childhood asthma: a nationwide population-based cohort study in Taiwan. Med (Baltim). 2016;95(41):e5109.","journal-title":"Med (Baltim)"},{"issue":"7","key":"3179_CR41","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMoa1515990","volume":"375","author":"WJ Sheehan","year":"2016","unstructured":"Sheehan WJ, Mauger DT, Paul IM, Moy JN, Boehmer SJ, Szefler SJ, et al. Acetaminophen versus Ibuprofen in Young children with mild persistent asthma. N Engl J Med. 2016;375(7):619\u201330.","journal-title":"N Engl J Med"},{"issue":"3","key":"3179_CR42","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/bjd.12674","volume":"170","author":"JL Corzo","year":"2014","unstructured":"Corzo JL, Zambonino MA, Mu\u00f1oz C, Mayorga C, Requena G, Urda A, et al. Tolerance to COX-2 inhibitors in children with hypersensitivity to nonsteroidal anti-inflammatory drugs. Br J Dermatol. 2014;170(3):725\u20139.","journal-title":"Br J Dermatol"},{"issue":"5","key":"3179_CR43","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/alr.21494","volume":"5","author":"HI Ertoy Karagol","year":"2015","unstructured":"Ertoy Karagol HI, Yilmaz O, Topal E, Ceylan A, Bakirtas A. Nonsteroidal anti-inflammatory drugs-exacerbated respiratory disease in adolescents. Int Forum Allergy Rhinol. 2015;5(5):392\u20138.","journal-title":"Int Forum Allergy Rhinol"},{"key":"3179_CR44","doi-asserted-by":"crossref","unstructured":"Guvenir H, Dibek Misirlioglu E, Vezir E, Toyran M, Ginis T, Civelek E et al. Nonsteroidal anti-inflammatory drug hypersensitivity among children. Allergy Asthma Proc. 2015;36(5):386\u201393.","DOI":"10.2500\/aap.2015.36.3858"},{"issue":"2","key":"3179_CR45","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.anai.2020.04.003","volume":"125","author":"O Yilmaz Topal","year":"2020","unstructured":"Yilmaz Topal O, Kulhas Celik I, Turgay Yagmur I, Toyran M, Civelek E, Karaatmaca B, et al. Results of NSAID provocation tests and difficulties in the classification of children with nonsteroidal anti-inflammatory drug hypersensitivity. Ann Allergy Asthma Immunol. 2020;125(2):202\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"3179_CR46","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jpeds.2005.03.055","volume":"147","author":"JS Debley","year":"2005","unstructured":"Debley JS, Carter ER, Gibson RL, Rosenfeld M, Redding GJ. The prevalence of ibuprofen-sensitive asthma in children: a randomized controlled bronchoprovocation challenge study. J Pediatr. 2005;147(2):233\u20138.","journal-title":"J Pediatr"},{"issue":"3","key":"3179_CR47","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/ppul.1118","volume":"32","author":"JS Goraya","year":"2001","unstructured":"Goraya JS, Virdi VS. To the editor: exacerbation of asthma by ibuprofen in a very young child. Pediatr Pulmonol. 2001;32(3):262.","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"3179_CR48","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40368-016-0233-0","volume":"17","author":"G King","year":"2016","unstructured":"King G, Byrne A, Fleming P. A case of severe NSAID exacerbated respiratory disease (NERD) following a dental procedure in a child. Eur Arch Paediatr Dent. 2016;17(4):277\u201381.","journal-title":"Eur Arch Paediatr Dent"},{"issue":"3","key":"3179_CR49","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/ppul.20552","volume":"42","author":"K Malmstr\u00f6m","year":"2007","unstructured":"Malmstr\u00f6m K, Kaila M, Kajosaari M, Syv\u00e4nen P, Juntunen-Backman K. Fatal asthma in Finnish children and adolescents 1976\u20131998: validity of death certificates and a clinical description. Pediatr Pulmonol. 2007;42(3):210\u20135.","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"3179_CR50","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1081-1206(10)62961-4","volume":"80","author":"R Menendez","year":"1998","unstructured":"Menendez R, Venzor J, Ortiz G. Failure of zafirlukast to prevent ibuprofen-induced anaphylaxis. Ann Allergy Asthma Immunol. 1998;80(3):225\u20136.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"3179_CR51","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/0310057X0503300218","volume":"33","author":"GM Palmer","year":"2005","unstructured":"Palmer GM. A teenager with severe asthma exacerbation following ibuprofen. Anaesth Intensive Care. 2005;33(2):261\u20135.","journal-title":"Anaesth Intensive Care"},{"issue":"5","key":"3179_CR52","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jaci.2010.08.023","volume":"126","author":"E Schnabel","year":"2010","unstructured":"Schnabel E, Heinrich J. Respiratory tract infections and not Paracetamol medication during infancy are associated with asthma development in childhood. J Allergy Clin Immunol. 2010;126(5):1071\u20133.","journal-title":"J Allergy Clin Immunol"},{"key":"3179_CR53","unstructured":"CRD. Chapter 4: systematic reviews of adverse effects. Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care. York Publishing Services; 2009."},{"key":"3179_CR54","unstructured":"Reeves B, Deeks J, Higgins J, Shea B, Tugwell P, Wells G. Chapter 24: Including non-randomized studies on intervention effects. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, editors. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. 6.3. Cochrane; 2022 [cited 2023 Apr 7]. https:\/\/training.cochrane.org\/handbook\/current\/chapter-24"},{"issue":"2","key":"3179_CR55","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/cea.12433","volume":"45","author":"J Riley","year":"2015","unstructured":"Riley J, Braithwaite I, Shirtcliffe P, Caswell-Smith R, Hunt A, Bowden V, et al. Randomized controlled trial of asthma risk with Paracetamol use in infancy\u2013a feasibility study. Clin Exp Allergy. 2015;45(2):448\u201356.","journal-title":"Clin Exp Allergy"},{"issue":"12","key":"3179_CR56","doi-asserted-by":"publisher","first-page":"e038296","DOI":"10.1136\/bmjopen-2020-038296","volume":"10","author":"E Tan","year":"2020","unstructured":"Tan E, Braithwaite I, McKinlay C, Riley J, Hoare K, Okesene-Gafa K, et al. Randomised controlled trial of Paracetamol or Ibuprofen, as required for fever and pain in the first year of life, for prevention of asthma at age 6 years: Paracetamol or Ibuprofen in the primary prevention of asthma in Tamariki (PIPPA Tamariki) protocol. BMJ Open. 2020;10(12):e038296.","journal-title":"BMJ Open"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03179-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-03179-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03179-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T22:02:12Z","timestamp":1724709732000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-03179-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3179"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-03179-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3486626\/v1","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,26]]},"assertion":[{"value":"24 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"OS and NS are current employees of Reckitt and may hold equity interest in Reckitt. LB and RS were compensated by Reckitt for activities related to execution of the study. MC and AB declare no competing interests. No other disclosures were reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"412"}}